Dr. Loibl Discusses GeparSepto Trial in Breast Cancer
Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.
Sibylle Loibl, MD, PhD, co-chair of the German Breast Group (GBG) and associate professor at the University of Frankfurt, discusses the GeparSepto trial in subgroups of patients with breast cancer.
Patients with HER2-positive disease were treated with pertuzumab (Perjeta) plus trastuzumab (Herceptin) in addition to chemotherapy. Both drugs were given for the entire 24 weeks, and trastuzumab was continued for up to 1 year.
In the HER2-positive population, hormone receptor (HR)-negative patients had a pathological complete response (pCR) rate that was much higher than the other 2 cohorts at 75%. This pCR rate is more important in patients with HER2-positive disease than in patients with triple-negative, says Loibl.
